Navigation Links
Valeant Pharmaceuticals Increases Proposed Price for Acquisition of ISTA Pharmaceuticals Inc. to $7.50 Per Share in Cash
Date:1/17/2012

MISSISSAUGA, Ontario, Canada, Jan. 17, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has increased from $6.50 to $7.50 per share in cash the proposed price of its previously  announced offer to acquire ISTA Pharmaceuticals Inc. (Nasdaq: ISTA).  Valeant also communicated to ISTA that Valeant believed that it could achieve a price of up to $8.50 per share, assuming that ISTA provides it selected confirmatory due diligence related to the company that is consistent with what Valeant expects to see.  Valeant reaffirmed that its proposal would only remain open until January 31, 2012.  A copy of a letter from Valeant to the Board of Directors of ISTA is attached to this press release. 

Since December 16, 2011, the date on which Valeant publicly announced its proposal to acquire ISTA at $6.50 per share in cash, ISTA's stock has traded in a range significantly higher than in the months prior to that announcement.  The proposed price of $7.50 per share represents a premium of approximately 94% over ISTA's 60-day volume weighted trading average of $3.87 on December 15, 2011, the last trading day before Valeant's public announcement of its offer.  An $8.50 per share price would constitute a premium of approximately 120%.

After repeated attempts to enter into acquisition negotiations, in December 2011 Valeant announced that it had made a proposal to the Board of Directors of ISTA to acquire the company for $6.50 per share in cash.  At that time, Valeant made clear that its proposal would remain in effect only until January 31, 2012.  Valeant again reiterated its January 31 deadline.

Valeant expressed its disappointment that the Board of Directors and management of ISTA have not been willing to meaningfully engage with Valeant on a timely basis to obtain the b
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Fleming Pharmaceuticals Sells Ocean, Nephrocaps, Other Branded Products to Valeant
2. Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
3. Valeant Pharmaceuticals Completes Acquisition of iNova
4. Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance
5. Valeant Pharmaceuticals Completes Acquisition of Dermik
6. Valeant Announces Successful Results From Phase III Onychomycosis Trials
7. Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
8. Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
9. Valeant Pharmaceuticals to Syndicate Incremental Term Loans
10. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
11. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... Company (NYSE: PG ) today announced that three ... (SEAP). The new members are: Caroline Hermans, ... Howard Frumkin – Dean, School of the Public Health at ... California Environmental Protection Agency "With key ...
... Fujirebio Diagnostics, Inc., today announced that the U.S. Food and ... CYFRA 21-1™ EIA assay to monitor disease progression during the ... is the first biomarker assay kit to be cleared by ... cancer. "The clearance of the CYFRA 21-1 assay ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer 2
(Date:7/25/2014)... July 25, 2014 According to the ... Wafer, Devices, Applications, and Geography - Analysis & Forecast ... substrate is expected to reach $3.01 Billion by 2020 ... Technology Market for devices is expected to reach $6.17 ... includes an in-depth analysis of application and geography. , ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 Agoura Hills ... special promotion on Zoom Whitening. Zoom Whitening is one of ... only available through a dental professional. This light-assisted treatment uses ... the structure of the tooth to break up stains that ... effective on coffee, tea, wine, soft drink and tobacco stains. ...
(Date:7/25/2014)... olefin is an olefin or an alkene with a double ... carbon chain, or between the 1st and 2nd carbon atom. ... (or normal). The alpha olefin market is a vital market, ... polyethylene co-monomers and synthetic lubricants, across a wide range of ... markets for alpha olefins; however, Asia-Pacific has emerged as a ...
(Date:7/25/2014)... inconclusive cancer screening test results among some patients is ... Gareen et al, published July 25 in Cancer ... false positive or other results of computed tomography (CT) ... by some in the medical community. , "Unsubstantiated ... be put to rest and not continue to delay ...
(Date:7/25/2014)... A report released by the Juvenile Diabetes ... 2013 (July 1, 2012- June 30, 2013). , Outside of ... is the largest single funder of type 1 diabetes research ... with most of the top research centers. There is ... 1 diabetes in the near future. , Since the 2008 ...
Breaking Medicine News(10 mins):Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 3Health News:ACR statement on cancer study regarding patient anxiety from CT lung cancer screening 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2
... N.M., April 15 Civility Mutual, based in,Santa ... and only membership,organization to offer education, training and ... residency directors with the,educational tools and assessments their ... the ACGME Outcomes Project., "Civility in health ...
... Utrecht, The Netherlands April 15, 2008 ... 60 percent increased risk of developing pneumonia compared ... first week following prescription and decreases gradually thereafter. ... American Geriatrics Society. , Antipsychotic drugs are frequently ...
... HUNTSVILLE, Ala., April 15 Open Biosystems, ... science research,tools for drug discovery, today announced ... pools for multiplexed RNAi screens. This,novel offering ... and,the ability to rapidly screen through thousands ...
... 15 /Xinhua-PRNewswire-FirstCall/ -- CNinsure,Inc. CISG, a leading ... China, today announced the signing of an ... Co., Ltd ("Minsheng Life,Insurance")., According to ... with Minsheng Life Insurance at both the ...
... April 15, 2008 -- Results of a phase ... high-dose, high-frequency subcutaneous Rebif (interferon beta-1a) provide clinical evidence ... to 30 months of continued therapy in patients with ... in the April 2008 issue of the Current Medical ...
... practical for treating human diseases, researchers must master the ... The Childrens Hospital of Philadelphia have advanced delivery techniques ... to a variety of gene therapy vectors and can ... at a disease site. , In an animal study, ...
Cached Medicine News:Health News:New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements 2Health News:Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 3Health News:Study shows that high-dose, high-frequency interferon produces no additional benefit 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 2Health News:In blood vessel stents, innovative materials allow better control, delivery of gene therapy 3
... for this age group?, ,Babies and young ... of an MDI. , ,Dry powder devices ... achieve efficiency. , ,Traditional nebulizers have high ... often used for this age group are inefficient ...
... Compact Compressor is for active patients who ... and everywhere. The compressor is small and ... optionsworldwide AC compatibility (100 to 240V), 12 ... the freedom to take aerosol treatments away ...
... Compact sporty design and ... XL the product of choice ... and performance. The CompAir XL ... cord storage compartment and a ...
... The 50 psi MaxiCompressor, ... designed to run 24 hours ... week. It features a tamper-proof ... against unintentional increases or decreases ...
Medicine Products: